Navigation Links
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
Date:12/7/2007

Celldex also receives approval from Health Canada to open clinical sites

and establishes a collaboration with the National Cancer Institute

PHILLIPSBURG, N.J., Dec. 7 /PRNewswire/ -- Celldex Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Celldex's CDX-110 for the treatment of EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is the most common and aggressive form of brain cancer. CDX-110 is an immunotherapy that targets the tumor-specific growth promoter EGFRvIII. Celldex Therapeutics announced a definitive merger agreement with AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) in October 2007.

In the ACTIVATE phase IIa study, CDX-110 treated GBM patients showed a median survival time of 30 months, more than a 100 percent increase in survival, versus the historical control's median of 14.5 months. The study has demonstrated a median time-to-progression of 13 months (p=0.0001) versus the historical control's median of 6.4 months. An extension study, ACT II, which combines CDX-110 with chemotherapy in a similar patient population, has not yet reached median time-to-progression or survival. However, preliminary progression free survival (PFS) and overall survival (OS) data in ACT II look very similar to the ACTIVATE experience, and the data suggest that chemotherapy and CDX-110 can be administered concurrently while still maintaining strong immune responses.

In September, Celldex randomized its first patient into ACT III, a definitive Phase II/III randomized study of CDX-110 with radiation and temozolomide in patients with newly-diagnosed GBM. The clinical trial is investigating the anticancer activity, impact on survival, a
'/>"/>

SOURCE Celldex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 According to Kalorama ... needed to make Big Data in healthcare a reality, ... As part of the American Recovery and Reinvestment Act, ... record (EMR) projects and penalties will start applying soon ... Information, in its complete study of the EMR industry, ...
(Date:8/19/2014)...  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management ... and Regeneron will host an IR Thematic Conference Call on Alirocumab ... 2014 , Baird 2014 Healthcare Conference at 4:05 ... , Citi,s 9 th Annual Biotech Conference at ... , Morgan Stanley Global Healthcare Conference at 8:45 ...
(Date:8/19/2014)... and MENLO PARK, Calif. , ... DMPI) ("DelMar" "the company") announced today a protocol amendment to ... been filed with the U.S. Food and Drug Administration (FDA) ... has been opened at three clinical trial sites in ... confirmed that gross proceeds of US$2.9 million have been raised ...
Breaking Medicine Technology:Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7
... Oct. 6 Complete,Genomics Inc., a newly launched, ... Systems Biology (ISB) today announced their,partnership to conduct ... of the project, Complete Genomics will use its ... samples provided by,ISB. Then, once proof-of-concept has been ...
... will host a conference call today, Monday, October ... to review the outcome of the interim analysis ... known as D9902B),clinical trial of PROVENGE(R) (sipuleucel-T), the ... advanced prostate,cancer., Those interested may ...
Cached Medicine Technology:Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2
(Date:8/20/2014)... (PRWEB) August 20, 2014 This ... line of software defined networking, high availability cloud ... portfolio of Resellers, while allowing OPEN-V to sell ... is pleased to work with OPEN-V on this ... Donald Hows, manager distribution channels at storageFOUNDRY. "Nautilus ...
(Date:8/19/2014)... BambooIndustry.com, a well-known bamboo product manufacturer and retailer, ... recently. The company is excited to reveal the new items, ... for all clients. Now, every customer can get a discounted ... until August 30. , The company’s deckings are made ... for supreme durability. They are perfect for a dining room, ...
(Date:8/19/2014)... Crosley Law Firm, PC has reached a confidential ... Star Bakery for an undisclosed amount. The two claimants, Pete ... of 2011, respectively. The injuries were caused by two different ... to the left hand of each man. , At the ... short-staffed, having lost 200 of its, 500 workers in connection ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, Skmen.com, an ... assortment of 2014 bohemian dresses . In addition to ... these elegant items. Now, all of them are available at ... puts emphasis on product design and quality. Its beautiful bohemian ... purple, blue and many others. Owing to its top quality ...
(Date:8/19/2014)... involved in multitasking and ways to train it have ... Institut universitaire de griatrie de Montral and the University ... predict the effectiveness of this training. Cooking while having ... or driving while listening to a radio show ... lives. Unfortunately, it decreases with age, which makes it ...
Breaking Medicine News(10 mins):Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Promotional Bamboo Deckings from Well-known Online Supplier BambooIndustry.com 2Health News:Crosley Law Firm Reaches Settlement for Hand Amputation Victims at Commercial Bakery 2Health News:2014 Bohemian Dresses Now for Sale at Skmen.com 2Health News:Targeted brain training may help you multitask better 2
... NEW YORK, Aug. 11 Healthcare reform has become a hot button ... one organization,s attempts to clear the air and separate fact from fiction. ... http://inr.mediaseed.tv/oneClip_C/?feed=_QhsLVZADdDFnJstv e QtY97yVQFUg6so , ... and photos for free and unrestricted use at http://www.medi ...
... counters effects of hormone therapy, study finds , TUESDAY, ... has worked well in a trial of men whose ... taking for prostate cancer, researchers report. , The drug, ... hopes to market for fracture prevention, not only in ...
... PHILADELPHIA A new study conducted at the ... in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy ... phase three FREEDOM-301 trial for the orally-inhaled migraine ... from symptoms such as pain, nausea and light ...
... team approach to preventive healthcare delivery for older adults ... Institute improves health and quality of life, decreased emergency ... second year the new model saved money for the ... in the third year, a year after the home-based ...
... , , , ... 11 Masimo (Nasdaq: MASI ), the ... pulse oximetry, and Oridion (SIX Swiss Exchange: ORIDN), a ... an agreement to establish compatibility and connectivity between Oridion ...
... Fla., Aug. 11 Jeff Korte, former Major with the Florida Division ... Investigative Unit (SIU) for Litigation Solutions, LLC. , ... enforcement experience to Litigation Solutions, spending the past 20 years with the ... in 2008. , , During his tenure ...
Cached Medicine News:Health News:New Bone-Building Drug Promising Against Prostate Cancer 2Health News:New Bone-Building Drug Promising Against Prostate Cancer 3Health News:Aging with GRACE: New health care delivery model improves outcomes, saves money 2Health News:Aging with GRACE: New health care delivery model improves outcomes, saves money 3Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 2Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 3Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 4Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 5Health News:Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream(TM)20 Portable Bedside Monitors into the Masimo Patient SafetyNet(TM) System 6Health News:Jeff Korte Named as SIU Director, Litigation Solutions, LLC 2
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
2.0 mm cup , straight shaft, Flat handle, length 125.0 mm....
Size 4 - 2.25 mm...
The Storz Protege is an anterior segment unit only....
Medicine Products: